The Pathogenesis of Acute Kidney Impairment in Patients With Multiple Myeloma

Advances in Chronic Kidney Disease

Volumn 19, Issue 5, 2012, Pages 282-286

  Batuman, Vecihi ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytokines; Epithelial mesenchymal transformation; Megalin cubilin; Myeloma casts; Tubulointerstitial fibrosis

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MITOGEN ACTIVATED PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; TAMM HORSFALL GLYCOPROTEIN; THALIDOMIDE;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; APOPTOSIS; DIALYSIS; ENDOCYTOSIS; FANCONI RENOTUBULAR SYNDROME; HUMAN; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE DISORDER; MULTIPLE MYELOMA; MYELOMA KIDNEY; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ACUTE KIDNEY INJURY; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY TUBULES, PROXIMAL; MULTIPLE MYELOMA; NEPHRITIS; NEPHRONS; UROMODULIN;

EID: 84865436018     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2012.04.009     Document Type: Review

References (49)

1. Hutchison C.A., Batuman V., Behrens J., et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 2011, 8:43-51.
2. Sengul S., Li M., Batuman V. Myeloma kidney: toward its prevention-with new insights from in vitro and in vivo models of renal injury. J Nephrol 2009, 22:17-28.
3. Li M., Balamuthusamy S., Simon E.E., Batuman V. Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells. Am J Physiol Renal Physiol 2008, 295:F82-F90.
4. Batuman V. Proximal tubular injury in myeloma. Contrib Nephrol 2007, 153:87-104.
5. Klassen R.B., Allen P.L., Batuman V., Crenshaw K., Hammond T.G. Light chains are a ligand for megalin. J Appl Physiol 2005, 98:257-263.
6. Sengul S., Zwizinski C., Simon E.E., Kapasi A., Singhal P.C., Batuman V. Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int 2002, 62:1977-1988.
7. Batuman V., Verroust P.J., Navar G.L., et al. Myeloma light chains are ligands for cubilin (gp280). Am J Physiol 1998, 275(2 Pt 2):F246-F254.
8. Batuman V., Guan S. Receptor-mediated endocytosis of immunoglobulin light chains by renal proximal tubule cells. Am J Physiol 1997, 272(4 Pt 2):F521-F530.
9. Peterson P.A., Berggard I. Urinary immunoglobulin components in normal, tubular, and glomerular proteinuria: quantities and characteristics of free light chains, IgG, IgA, and Fc-gamma fragment. Eur J Clin Invest 1971, 1:255-264.
10. Messiaen T., Deret S., Mougenot B., et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine (Baltimore) 2000, 79:135-154.
11. Nakhoul N., Batuman V. Role of proximal tubules in the pathogenesis of kidney disease. Contrib Nephrol 2011, 169:37-50.
12. Khan A.M., Li M., Balamuthusamy S., Maderdrut J.L., Simon E.E., Batuman V. Myeloma light chain-induced renal injury in mice. Nephron Exp Nephrol 2010, 116:e32-e41.
13. Li M., Hering-Smith K.S., Simon E.E., Batuman V. Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells. Nephrol Dial Transplant 2008, 23:860-870.
14. Arimura A., Li M., Batuman V. Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 2006, 107:661-668.
15. Sengul S., Zwizinski C., Batuman V. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol 2003, 284:F1245-F1254.
16. Pote A., Zwizinski C., Simon E.E., Meleg-Smith S., Batuman V. Cytotoxicity of myeloma light chains in cultured human kidney proximal tubule cells. Am J Kidney Dis 2000, 36:735-744.
17. Guan S., El-Dahr S., Dipp S., Batuman V. Inhibition of Na-K-ATPase activity and gene expression by a myeloma light chain in proximal tubule cells. J Invest Med 1999, 47:496-501.
18. Batuman V., Guan S., O'Donovan R., Puschett J.B. Effect of myeloma light chains on phosphate and glucose transport in renal proximal tubule cells. Renal Physiol Biochem 1994, 17:294-300.
19. Batuman V., Dreisbach A.W., Cyran J. Light-chain binding sites on renal brush-border membranes. Am J Physiol 1990, 258(5 Pt 2):F1259-F1265.
20. Batuman V., Sastrasinh M., Sastrasinh S. Light chain effects on alanine and glucose uptake by renal brush border membranes. Kidney Int 1986, 30:662-665.
21. Basnayake K., Ying W.Z., Wang P.X., Sanders P.W. Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J Am Soc Nephrol 2010, 21:1165-1173.
22. Huang Z.Q., Kirk K.A., Connelly K.G., Sanders P.W. Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J Clin Invest 1993, 92:2975-2983.
23. Huang Z.Q., Sanders P.W. Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab Invest 1995, 73:810-817.
24. Huang Z.Q., Sanders P.W. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest 1997, 99:732-736.
25. Sanders P.W. Light chain-mediated tubulopathies. Contrib Nephrol 2011, 169:262-269.
26. Sanders P.W., Booker B.B. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992, 89:630-639.
27. Sanders P.W., Booker B.B., Bishop J.B., Cheung H.C. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest 1990, 85:570-576.
28. Sanders P.W., Herrera G.A., Chen A., Booker B.B., Galla J.H. Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J Clin Invest 1988, 82:2086-2096.
29. Sanders P.W., Herrera G.A., Galla J.H. Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int 1987, 32:851-861.
30. Sanders P.W., Herrera G.A., Kirk K.A., Old C.W., Galla J.H. Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest 1991, 64:527-537.
31. Sanders P.W., Herrera G.A., Lott R.L., Galla J.H. Morphologic alterations of the proximal tubules in light chain-related renal disease. Kidney Int 1988, 33:881-889.
32. Ying W.Z., Sanders P.W. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol 2001, 158:1859-1866.
33. Ying W.Z., Wang P.X., Aaron K.J., Basnayake K., Sanders P.W. Immunoglobulin light chains activate nuclear factor-kappaB in renal epithelial cells through a Src-dependent mechanism. Blood 2011, 117:1301-1307.
34. Aucouturier P., Bauwens M., Khamlichi A.A., et al. Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi's syndrome. J Immunol 1993, 150(8 Pt 1):3561-3568.
35. Decourt C., Rocca A., Bridoux F., et al. Mutational analysis in murine models for myeloma-associated Fanconi's syndrome or cast myeloma nephropathy. Blood 1999, 94:3559-3566.
36. Sirac C., Bridoux F., Essig M., Devuyst O., Touchard G., Cogne M. Toward understanding renal Fanconi syndrome: step by step advances through experimental models. Contrib Nephrol 2011, 169:247-261.
37. Galla J.H., Herrera G.A., Sanders P.W. Differential toxicity of human Bence-Jones proteins in the rat proximal convoluted tubule in vivo. Contrib Nephrol 1988, 68:198-202.
38. Herlitz L.C., Roglieri J., Resta R., Bhagat G., Markowitz G.S. Light chain proximal tubulopathy. Kidney Int 2009, 76:792-797.
39. Sirac C., Bridoux F., Carrion C., et al. Role of the monoclonal kappa chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome. Blood 2006, 108:536-543.
40. Wang P.X., Sanders P.W. Immunoglobulin light chains generate hydrogen peroxide. J Am Soc Nephrol 2007, 18:1239-1245.
41. Sanders P.W. Potential role of colchicine in the prevention of cast nephropathy from Bence Jones proteins. Contrib Nephrol 1993, 101:104-108.
42. Tanner G.A., Knopp L.C. Glomerular blood flow after single nephron obstruction in the rat kidney. Am J Physiol 1986, 250(1 Pt 2):F77-F85.
43. Tanner G.A., Evan A.P. Glomerular and proximal tubular morphology after single nephron obstruction. Kidney Int 1989, 36:1050-1060.
44. Solomon A., Weiss D.T., Kattine A.A. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991, 324:1845-1851.
45. Myatt E.A., Westholm F.A., Weiss D.T., Solomon A., Schiffer M., Stevens F.J. Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition. Proc Natl Acad Sci USA 1994, 91:3034-3038.
46. Kumar V., Elkins S., Gaston R.S., et al. Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant. Clin Transpl 2009, 439-441.
47. Dimopoulos M.A., Terpos E., Chanan-Khan A., et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010, 28:4976-4984.
48. Ludwig H., Zojer N. Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. Nat Rev Clin Oncol 2010, 7:289-294.
49. Hutchison C.A., Bradwell A.R., Cook M., et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009, 4:745-754.